Vemurafenib-cobimetinib in patients with progressive BRAF-mutated metastatic malignant melanoma

Authors

Keywords:

metastatic melanoma, BRAF mutated, BRAF/MEK inhibitors

Abstract

Introduction: Melanoma is a rare skin tumor, but with high mortality; molecular studies and targeted therapies currently modify the main response indicators of metastatic disease.

Objective: To characterize patients diagnosed with metastatic malignant cutaneous melanoma with BRAF gene mutation, toxicity and response to treatment with BRAF/MEK inhibitors (vemurafenib and cobimetinib), in second line.
Methods: A longitudinal and observational study of 13 patients was carried out, treated at the National Institute of Oncology and Radiobiology and at the "Hermanos Ameijeiras" Hospital, from January 2017 to December 2019. Summary measures of descriptive statistics were used and survival estimates by the KaplanMeier method.

Results: 92.3% of the patients had white skin and the mean age at diagnosis was 45 years. All patients had extended surgery of the primary lesion, and first-line adjuvant chemotherapy (n = 9), radiotherapy (n = 8) and interferon α2r (n = 6). Visceral metastases were identified in more than 50% (69.2% in the lung), all with good general condition. The nodular subtype and location in the lower limbs predominated. The main toxicities were dermatological (photosensitivity and grade II rash). Median overall survival was 15.7 months (95% CI = 3.99 - 27.47).

Conclusions: Most melanoma patients are young and fair-skinned, and the combination of vemurafenib/cobimetinib is safe and also shows a benefit in the clinical response of previously treated patients.

Downloads

Download data is not yet available.

Author Biographies

Iraida Caballero Aguirrechu, Hospital Hermanos Ameijeiras

Especialista 2do Grado oncologia. Ms.C Infectología, Profesor e Investigador Auxiliar

Yanelis Mir Espinosa, Instituto Nacional de Oncologia y Radiobiologia

Especialista 1er grado oncologia, profesor Auxiliar

Rigoberto García Gómez, Hospital Hermanos Ameijeiras

Especialista 2do grado Dermatología. Dr.C. Profesor e Investigador Titular

Susel Quesada Peña, Hospital hermanos Ameijeiras

Especialista Bioestadisticas, Profesor e Investigador Auxiliar

Jorge Luis Soriano García, Hospital Hermanos Ameijeiras

Dr.C. Profesor e Investigador Titular. Especialista 2do Grado Oncologia

Marta de la caridad Osorio Rodríguez, Hospital Hermanos Ameijeiras

Dr.C. Especialista 2do Grado Oncología. Profesor e Investigador Titular

Elias Antonio Gracia Medina, Instituto Nacional de Oncología y Radiobiología

Especialista 2do Grado Oncología. Profesor e Investigador Auxiliar

Alexander Ortega Carballosa, Hospital Hermanos Ameijeiras

Especialista 2do grado Inmunología. Profesor e Investigador Asistente

Ernesto Arteaga, Hospital Hermanos Ameijeiras

Especialista 2do grado Anatomia Patológica. Profesor e Investigador Auxiliar

Annabelle Castro Turuseta, Hospital hermanos Ameijeiras

Especialista 2do grado dermatologia. Profesor e Investigador Asistente

References

Siegel MPH, Miller MPH, Fuchs BS, Jemal DVM. Cancer statistic, 2022. CA: a Journal Clinicians Open Access, 2022;72(1), 7–33. https://doi.org/10.3322/caac.21708

Gershemwald JE, Scolyer RA, et al. Melanoma staging and classification: AJCC 8th Edition and Beyond. Ann Surg Oncol, 2018; 25: 2105-2110.

https://doi.org/10.1245/s10434-018-6513-7

A. Kocsis L. Karsko Zs. Kurgyis Zs. Besenyi L. Pavics E. Dosa-Racz, et al. Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis. Pathology & Oncology Research 2020; 26:1861–1868. https://doi.org/10.1007/s12253-019-00769-z

A. Sosa, E. Lopez Cadena, C. Simon Olive, N. Karachaliou, and R. Rosell, “Clinical assessment of immune-related adverse events,” Therapeutic Advances in Medical Oncology 2018; vol. 10. https://doi.org 10.1177/1758835918764628

Menzer C, Menzies AM, Carlino MS, et al. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. J Clin Oncol 2019; 37:3142. https://doi.org/10.1200/JCO.19.00489

Manfredi L, Meyer N, Tournier E et al. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma. Acta Derm Venereol 2016; 96: 630–634.

http://doi.org/10.2340/00015555-2326

Djavid AR, Stonesifer C, Fullerton BT, Wang SW, Tartaro MA, Kwinta BD, Grimes JM, Geskin LJ, Saenger YM. Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence. Cancers. 2021; 13(19):4914. https://doi.org/10.3390/cancers13194914

Koshenkov VP, Broucek J, Kaufman HL. Surgical management of melanoma. Cancer Treat Res 2016; 167: 149-179. https://doi.org/10.1007/978-3-319-22539-56

Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-25. https://doi.org/:10.1200/JCO.2004.04.165

Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer 2017; 17:676–691 https://doi.org/10.1038/nrc.2017.79

Ross JS, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016; 138:881–890. https://doi.org/10.1002/ijc.29825

Paolo A. Ascierto, Brigitte Dréno, James Larkin, et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res 2021;27:5225–35. https://doi: 10.1158/1078-0432.CCR-21-0809

Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 2017; 28:2581. https://doi.org/10.1093/annonc/mdx339

Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17:1248–1260. https://doi.org/10.1016/S1470-2045(16)30122-X

Mackiewicz J, Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp Oncol (Pozn) 2018; 22 (1A): 68–72 DOI: https://doi.org/10.5114/wo.2018.73890

Gautham G, Vaidhyanathan S, Resman BW, Markovic S, Sarkaria J, et al. Challenges in the delivery of therapies to melanoma brain metastases Curr Pharmacol Rep. 2016 December ; 2(6): 309–325. https://doi.org 10.1007/s40495-016-0072-z.

Vergalasova I, Liu H, Alonso-Basanta M, Dong L, Li J, Nie K, Shi W, et al. Multi-Institutional Dosimetric Evaluation of Modern Day Stereotactic Radiosurgery (SRS) Treatment Options for Multiple Brain Metastases. Front Oncol 2019; 9:483. https://doi.org/10.3389/fonc.2019.00483

B. Gençler and M. Gönül, “Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature,” Dermatology Research and Practice, vol. 2016, Article ID 5361569, 6 pages, 2016. https://doi.org/10.1155/2016/5361569

Downloads

Published

2023-02-20

How to Cite

1.
Caballero Aguirrechu I, Mir Espinosa Y, García Gómez R, Quesada Peña S, Soriano García JL, Osorio Rodríguez M de la caridad, et al. Vemurafenib-cobimetinib in patients with progressive BRAF-mutated metastatic malignant melanoma. Rev Cubana Inv Bioméd [Internet]. 2023 Feb. 20 [cited 2025 Sep. 20];42(1). Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/2472

Issue

Vol. 42 (2023)

Section

ARTÍCULOS ORIGINALES

License

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes: Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC-BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).

Como Revista Cubana de Investigaciones Biomédicas forma parte de la red SciELO, una vez los artículos sean aceptados para entrar al proceso editorial (revisión), estos pueden ser depositados por parte de los autores, si estan de acuerdo, en SciELO preprints, siendo actualizados por los autores al concluir el proceso de revisión y las pruebas de maquetación.